<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03200860</url>
  </required_header>
  <id_info>
    <org_study_id>2017-001679-22</org_study_id>
    <nct_id>NCT03200860</nct_id>
  </id_info>
  <brief_title>Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure</brief_title>
  <acronym>EMPA-RESPONSE</acronym>
  <official_title>Randomized, Double Blind, Placebo Controlled, Multicenter Pilot Study on the Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute decompensated heart failure is the fastest growing disease in the world and the leading
      cause of hospital admissions worldwide. Short term mortality and rehospitalization are
      extremely high (20-30% within 3-6 months) and there is no therapy available that improves
      clinical outcome in these patients. Empagliflozin is a selective inhibitor of sodium glucose
      co-transporter with diuretic and renal- protective properties. In patients with type 2
      diabetes at high risk for cardiovascular events, empagliflozin reduced the risk of
      hospitalization for heart failure by 35%. Based on the promising pharmacological profile of
      empagliflozin in relation to the needs for treatment of acute decompensated heart failure, we
      hypothesize that empagliflozin exerts positive effects in acute decompensated heart failure,
      with or without diabetes,

      This is a randomized, placebo-controlled, double-blind, parallel group, multicenter study in
      subjects admitted for acute decompensated heart failure. Eighty eligible subjects will be
      randomized in a 1:1 ratio to receive either empagliflozin 10 mg/day or matched placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, placebo-controlled, double-blind, parallel group, multicenter study in
      subjects admitted for acute decompensated heart failure. Eighty eligible subjects will be
      randomized in a 1:1 ratio to receive either empagliflozin 10 mg/day or matched placebo.

      Treatment will be continued until 30 days after index event, and primary efficacy
      measurements will be carried out during hospitalization and safety events until 60 days after
      index hospitalisation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 18, 2017</start_date>
  <completion_date type="Actual">September 18, 2019</completion_date>
  <primary_completion_date type="Actual">September 18, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, placebo-controlled, double-blind, parallel group, multicenter study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blind, placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>From baseline to Day 4</time_frame>
    <description>Change in Dyspnea on VAS analogue scale (AUC)
VAS Score is a measure/scale where patients on a scale from 0 to 100 can assign their current dyspnea score. 0 means there can be no worse dyspnea, 100 means it cannot get any better (perfect).
The change in Dyspnea VAS means higher score is better outcomes.
Individual changes in VAS score are be visualized (virtually) as a curve where the X-axis shows study day baseline to day 4, and y-axis shows VAS score. Using this approach, area under the curves for each study day (trapezoids) can be calculated, and added together, resulting in an overall VAS AUC score (mmxh) and change in VAS can be caculated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diuretic Response</measure>
    <time_frame>Total weight change from baseline to Day 4</time_frame>
    <description>Weight change from baseline per 40 mg of Furosemide equivalent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>within 60 days</time_frame>
    <description>Hospital stay of Index admission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma NTproBNP</measure>
    <time_frame>From baseline to Day 4</time_frame>
    <description>Change in NTproBNP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death and/or Heart Failure Re-admission</measure>
    <time_frame>Day 30</time_frame>
    <description>Death and/or heart failure re-admission at day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhospital Worsening Heart Failure, All Cause Mortality or Heart Failure Readmission at Day 60</measure>
    <time_frame>60 days</time_frame>
    <description>Inhospital Worsening Heart Failure or All Cause mortality or Heart Failure Readmission at day 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>60 day</time_frame>
    <description>All Cause Mortality at 60 days</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>60 days</time_frame>
    <description>SAE including all cause mortality. Per request Clintrials.gov different from Protocol definition</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Heart Failure Acute</condition>
  <condition>Heart Failure，Congestive</condition>
  <condition>Heart Failure; With Decompensation</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Empagliflozin 10 mg daily, oral, 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo 10 mg daily, oral, 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 10 MG</intervention_name>
    <description>10 mg daily, oral, 30 days</description>
    <arm_group_label>Empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Matching Placebo, 10 mg daily, oral, 30 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female &gt;18 years of age; Women of non-child-bearing potential must have a
             documentation of surgical sterilization (hysterectomy and/or bilateral oophorectomy)
             OR must have experienced menopause (no menses for &gt;12 months). Women of child bearing
             potential must have a negative pregnancy test, AND must use highly effective methods
             of contraception during treatment with IP plus 5 days after the end of study drug
             administration.

          -  Hospitalized for AHF; AHF is defined as including all of the followings measured at
             any time between presentation (including the emergency department) and the end of
             screening:

               1. Dyspnea at rest or with minimal exertion

               2. Signs of congestion, such as edema, rales, and/or congestion on chest radiograph

               3. BNP ≥350 pg/mL or NT-proBNP ≥1,400 pg/mL (for patients with AF: BNP≥500 pg/mL or
                  NT-proBNP ≥2,000 pg/mL)

               4. Treated with loop diuretics at screening

          -  Able to be randomized within 24 hours from presentation to the hospital

          -  Able and willing to provide freely given written informed consent

          -  eGFR (CKD-EPI) ≥30 ml/min/1.73m2 between presentation and randomization

        Exclusion Criteria:

          -  Diabetes Mellitus Type I

          -  Dyspnea primarily due to non-cardiac causes

          -  Cardiogenic shock

          -  Acute coronary syndrome within 30 days prior to randomization

          -  Planned or recent percutaneous or surgical coronary intervention within 30 days prior
             to randomization

          -  Signs of keto-acidosis and/or hyperosmolar hyperglaecemic syndrome (pH&gt;7.30 and
             glucose &gt;15 mmol/L and HCO3&gt;18 mmol/L)

          -  Pregnant or nursing (lactating) women

          -  Current participation in any interventional study

          -  Inability to follow instructions or comply with follow-up procedures

          -  Any other medical conditions that may put the patient at risk or influence study
             results in the investigator's opinion, or that the investigator deems unsuitable for
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriaan Voors, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>Den Bosch</city>
        <state>Brabant</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TREANT Zorggroep</name>
      <address>
        <city>Emmen</city>
        <state>Drenthe</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antonius Ziekenhuis</name>
      <address>
        <city>Sneek</city>
        <state>Friesland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ISALA Klinieken</name>
      <address>
        <city>Zwolle</city>
        <state>Overijssel</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.</citation>
    <PMID>26378978</PMID>
  </reference>
  <reference>
    <citation>Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.</citation>
    <PMID>27299675</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2017</study_first_posted>
  <results_first_submitted>January 8, 2020</results_first_submitted>
  <results_first_submitted_qc>February 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 19, 2020</results_first_posted>
  <last_update_submitted>February 9, 2020</last_update_submitted>
  <last_update_submitted_qc>February 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>A.A.Voors</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>diuretic response</keyword>
  <keyword>empagliflozin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT03200860/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT03200860/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Empagliflozin</title>
          <description>Empagliflozin 10 mg daily, oral, 30 days
Empagliflozin 10 MG: 10 mg daily, oral, 30 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching Placebo 10 mg daily, oral, 30 days
Placebo Oral Tablet: Matching Placebo, 10 mg daily, oral, 30 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Empagliflozin</title>
          <description>Empagliflozin 10 mg daily, oral, 30 days
Empagliflozin 10 MG: 10 mg daily, oral, 30 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching Placebo 10 mg daily, oral, 30 days
Placebo Oral Tablet: Matching Placebo, 10 mg daily, oral, 30 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79" lower_limit="73" upper_limit="83"/>
                    <measurement group_id="B2" value="73" lower_limit="61" upper_limit="83"/>
                    <measurement group_id="B3" value="76" lower_limit="68" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NTproBNP</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4406" lower_limit="2873" upper_limit="6979"/>
                    <measurement group_id="B2" value="6168" lower_limit="3180" upper_limit="10489"/>
                    <measurement group_id="B3" value="4918" lower_limit="3062" upper_limit="9555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dyspnea</title>
        <description>Change in Dyspnea on VAS analogue scale (AUC)
VAS Score is a measure/scale where patients on a scale from 0 to 100 can assign their current dyspnea score. 0 means there can be no worse dyspnea, 100 means it cannot get any better (perfect).
The change in Dyspnea VAS means higher score is better outcomes.
Individual changes in VAS score are be visualized (virtually) as a curve where the X-axis shows study day baseline to day 4, and y-axis shows VAS score. Using this approach, area under the curves for each study day (trapezoids) can be calculated, and added together, resulting in an overall VAS AUC score (mmxh) and change in VAS can be caculated</description>
        <time_frame>From baseline to Day 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin</title>
            <description>Empagliflozin 10 mg daily, oral, 30 days
Empagliflozin 10 MG: 10 mg daily, oral, 30 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo 10 mg daily, oral, 30 days
Placebo Oral Tablet: Matching Placebo, 10 mg daily, oral, 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Dyspnea</title>
          <description>Change in Dyspnea on VAS analogue scale (AUC)
VAS Score is a measure/scale where patients on a scale from 0 to 100 can assign their current dyspnea score. 0 means there can be no worse dyspnea, 100 means it cannot get any better (perfect).
The change in Dyspnea VAS means higher score is better outcomes.
Individual changes in VAS score are be visualized (virtually) as a curve where the X-axis shows study day baseline to day 4, and y-axis shows VAS score. Using this approach, area under the curves for each study day (trapezoids) can be calculated, and added together, resulting in an overall VAS AUC score (mmxh) and change in VAS can be caculated</description>
          <units>mmxh</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1264" spread="1211"/>
                    <measurement group_id="O2" value="1650" spread="1240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diuretic Response</title>
        <description>Weight change from baseline per 40 mg of Furosemide equivalent</description>
        <time_frame>Total weight change from baseline to Day 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin</title>
            <description>Empagliflozin 10 mg daily, oral, 30 days
Empagliflozin 10 MG: 10 mg daily, oral, 30 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo 10 mg daily, oral, 30 days
Placebo Oral Tablet: Matching Placebo, 10 mg daily, oral, 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Diuretic Response</title>
          <description>Weight change from baseline per 40 mg of Furosemide equivalent</description>
          <units>kg/40 mg Furosemide equivalent at day 4</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.44"/>
                    <measurement group_id="O2" value="-0.12" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Length of Stay</title>
        <description>Hospital stay of Index admission</description>
        <time_frame>within 60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin</title>
            <description>Empagliflozin 10 mg daily, oral, 30 days
Empagliflozin 10 MG: 10 mg daily, oral, 30 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo 10 mg daily, oral, 30 days
Placebo Oral Tablet: Matching Placebo, 10 mg daily, oral, 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay</title>
          <description>Hospital stay of Index admission</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="6" upper_limit="10"/>
                    <measurement group_id="O2" value="8" lower_limit="6" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma NTproBNP</title>
        <description>Change in NTproBNP</description>
        <time_frame>From baseline to Day 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin</title>
            <description>Empagliflozin 10 mg daily, oral, 30 days
Empagliflozin 10 MG: 10 mg daily, oral, 30 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo 10 mg daily, oral, 30 days
Placebo Oral Tablet: Matching Placebo, 10 mg daily, oral, 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma NTproBNP</title>
          <description>Change in NTproBNP</description>
          <units>% change in NTproBNP at day 4</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46" spread="32"/>
                    <measurement group_id="O2" value="-42" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.63</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death and/or Heart Failure Re-admission</title>
        <description>Death and/or heart failure re-admission at day 30</description>
        <time_frame>Day 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin</title>
            <description>Empagliflozin 10 mg daily, oral, 30 days
Empagliflozin 10 MG: 10 mg daily, oral, 30 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo 10 mg daily, oral, 30 days
Placebo Oral Tablet: Matching Placebo, 10 mg daily, oral, 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Death and/or Heart Failure Re-admission</title>
          <description>Death and/or heart failure re-admission at day 30</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inhospital Worsening Heart Failure, All Cause Mortality or Heart Failure Readmission at Day 60</title>
        <description>Inhospital Worsening Heart Failure or All Cause mortality or Heart Failure Readmission at day 60</description>
        <time_frame>60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin</title>
            <description>Empagliflozin 10 mg daily, oral, 30 days
Empagliflozin 10 MG: 10 mg daily, oral, 30 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo 10 mg daily, oral, 30 days
Placebo Oral Tablet: Matching Placebo, 10 mg daily, oral, 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Inhospital Worsening Heart Failure, All Cause Mortality or Heart Failure Readmission at Day 60</title>
          <description>Inhospital Worsening Heart Failure or All Cause mortality or Heart Failure Readmission at day 60</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality</title>
        <description>All Cause Mortality at 60 days</description>
        <time_frame>60 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin</title>
            <description>Empagliflozin 10 mg daily, oral, 30 days
Empagliflozin 10 MG: 10 mg daily, oral, 30 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo 10 mg daily, oral, 30 days
Placebo Oral Tablet: Matching Placebo, 10 mg daily, oral, 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <description>All Cause Mortality at 60 days</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Serious Adverse Events</title>
        <description>SAE including all cause mortality. Per request Clintrials.gov different from Protocol definition</description>
        <time_frame>60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin</title>
            <description>Empagliflozin 10 mg daily, oral, 30 days
Empagliflozin 10 MG: 10 mg daily, oral, 30 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching Placebo 10 mg daily, oral, 30 days
Placebo Oral Tablet: Matching Placebo, 10 mg daily, oral, 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>SAE including all cause mortality. Per request Clintrials.gov different from Protocol definition</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cardiovascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory/Pulmonary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal/Urinary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infectious</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Cause Mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Empagliflozin</title>
          <description>Empagliflozin 10 mg daily, oral, 30 days
Empagliflozin 10 MG: 10 mg daily, oral, 30 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching Placebo 10 mg daily, oral, 30 days
Placebo Oral Tablet: Matching Placebo, 10 mg daily, oral, 30 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening Heart Failure</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypovolemic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Heart Failure</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening Renal Function</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>S. Aureus Bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Renal/Urinary</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="40"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limited number of patients
Screened many more patients then were included
no standardized protocol for inhospital treatment for HF</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Prof. dr. A.A. Voors</name_or_title>
      <organization>University Medical Center Groningen - Department of Cardiology</organization>
      <phone>0031503616161</phone>
      <email>a.a.voors@umcg.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

